Use of long-term suppressive acyclovir after hematopoietic stem-cell transplantation: impact on herpes simplex virus (HSV) disease and drug-resistant HSV disease.


Autoria(s): Erard Veronique; Wald Anna; Corey Lawrence; Leisenring Wendy M.; Boeckh Michael
Data(s)

2007

Resumo

The effect that long-term use of suppressive acyclovir (ACV) has on both overall herpes simplex virus (HSV) disease and ACV-resistant HSV disease was examined in 3 consecutive cohorts of hematopoietic stem-cell transplant (HCT) recipients (n=2049); cohort 1 received ACV for 30 days after HCT, cohort 2 received it for 1 year after HCT, and cohort 3 received it for an extended period (i.e., >1 year) if the patient's immunosuppression continued after 1 year. The 2-year probability of HSV disease was 31.6% (95% confidence interval [CI], 28.0%-35%) in cohort 1, 3.9% (95% CI, 2.7%-5.2%) in cohort 2, and 0% in cohort 3 (P<.001). ACV-resistant HSV disease developed in 10 patients in cohort 1 (2-year probability, 1.3% [95% CI, 0.8%-2.7%]), in 2 patients in cohort 2 (2-year probability, 0.2% [95% CI, 0%-0.8%]; P=.006), and in 0 patients in cohort 3 (cohort 2 vs. cohort 3, P=.3). Long-term use of suppressive prophylactic ACV appears to prevent the emergence of drug-resistant HSV disease in HCT.

Identificador

http://serval.unil.ch/?id=serval:BIB_8A2E6E8F0FBB

isbn:0022-1899

pmid:17570114

doi:10.1086/518938

isiid:000247803100014

Idioma(s)

en

Fonte

Journal of Infectious Diseases, vol. 196, no. 2, pp. 266-270

Palavras-Chave #Acyclovir/administration & dosage; Adolescent; Adult; Aged; Antiviral Agents/administration & dosage; Child; Child, Preschool; Drug Administration Schedule; Drug Resistance, Viral; Hematopoietic Stem Cell Transplantation; Herpes Simplex/prevention & control; Humans; Infant; Longitudinal Studies; Middle Aged; Retrospective Studies; Simplexvirus/drug effects
Tipo

info:eu-repo/semantics/article

article